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Our objective was to analyse the relationship between circulating cytokines, autoantibodies, acute phase reactants, and disease
activity in DMARDs-na¨ ıve rheumatoid arthritis (RA) patients (n = 140). All cytokines were signiﬁcantly higher in the RA cohort
than in healthy controls. Moderate-to-strong positive intercorrelations were observed between Th1/Th2/macrophage/ﬁbroblast-
derived cytokines. RF correlated signiﬁcantly with IL-1β, IL-2, IL-4, IL-10, IL-12, G-CSF, GM-CSF, IFN-γ,a n dT N F( P<. 0001),
and aCCP and aMCV with IL-1β, IL-2, IL-4, and IL-10 (P<. 0002), while IL-6 correlated best with the acute phase reactants,
CRP, and SAA (P<. 0001). In patients with a DAS28 score of ≥5.1, IFN-γ,I L - 1 β,I L - 1 R a ,T N F ,G M - C S F ,a n dV E G Fw e r e
signiﬁcantlycorrelated (P<. 04–.001)with high diseaseactivity (HDA).Circulating cytokines in RAreﬂect a multifaceted increase
in immune reactivity encompassing Th1 and Th2 cells, monocytes/macrophages, and synovial ﬁbroblasts, underscored by strong
correlationsbetween thesecytokines,aswellastheirrelationshipswithRF,aCCP,andaMCV,withsomecytokinesshowingpromise
as biomarkers of HDA.
1.Introduction
The triggering events in rheumatoid arthritis (RA), espe-
cially the identity of the primary autoantigen(s), await
conclusivecharacterization.Nonetheless,itiswellrecognized
that ongoing inﬂammation of the peripheral joints with
accompanying tissue damage involves complex, cytokine-
driveninteractions between resident synovial and inﬁltrating
inﬂammatory cells [1–3], particularly T-helper 1 (Th1) cells
oftheeﬀector-memoryphenotype[4–6].Recentstudieshave
suggested that chronic inﬂammation in the rheumatoid joint
may result from the sustained activation/dysregulation of
inﬂammatory cytokine networks which operate indepen-
dently of triggering autoantigens and T-cell receptor (TCR)
ligation [7–9]. In this setting, two mechanisms, probably
interactive, have been identiﬁed which appear to main-
tain autoantigen-independent production of inﬂammatory
cytokines. These are (i) direct activation of a subset of
eﬀector-memory Th1 cells by cytokines signaling via the
interleukin-2 receptor (IL-2R) common γ-chain in combi-
nation with IL-12 and IL-18, with resultant generation of
interferon-γ (IFN-γ)[ 10, 11] and (ii) continuous activation2 Mediators of Inﬂammation
of immune and inﬂammatory cells, including Th1 cells, via
interaction of Toll-like receptors (TLRs) with extracellular
matrix components released from damaged host tissues
[12–15].
Because of the critical role of cytokine networks in
perpetuating inﬂammatory responses in the rheumatoid
joint,circulating,and/orsynovial cytokinesareconsideredto
be ideal biomarkers to monitor disease onset, development
and progression, either directly using cytokine multiplex
immunoassays or indirectly by gene proﬁling approaches
[16–20]. To date, however, relatively few studies have been
reported in which circulating cytokine proﬁles have been
used either as a strategy to predict disease severity and
outcome in RA, or to provide insights into immunopatho-
genesis. Those which have been described have consistently
documented signiﬁcant elevations in the concentrations of
a range of circulating proinﬂammatory cytokines [16, 21–
25]. Nevertheless, these studies need to be corroborated and
extended in larger groups of patients not only to establish
circulating cytokine proﬁles in RA, but also to identify
inter-relationships between cytokines of diﬀerent cellular
origins and their associations with conventional biomarkers
and clinical markers of disease activity, and their predictive
potential.
In the current study, we have measured the concentra-
tions of a range of circulating anti-inﬂammatory and proin-
ﬂammatory cytokinesinarelativelylargecohort(n = 140)of
predominantlyAfricanpatientswithearly,disease modifying
antirheumatic drug-na¨ ıve RA. Vascular endothelial growth
factor (VEGF), which is produced by both macrophages and
ﬁbroblasts [26, 27], and which appears to correlate with
disease activity and progression [28, 29], was included in the
multiplex analysis.
2.PatientsandMethods
2.1. Patients. A cohort of 140 patients, who met the 1987
AmericanCollegeofRheumatologycriteriaforRA[30],were
disease-modifying antirheumatic drug(DMARD)na¨ ıve, had
disease duration of ≤2 years, and seen at two tertiary
hospitals in South Africa, were studied. All patients were
HIV-negative and receiving treatment with either diclofenac
(majority) or naproxen at the time of recruitment. The 28-
joint disease activity score-CRP 28 (DAS28-CRP) [31, 32]
and modiﬁed Health Questionnaire Disability Index (HAQ-
DI) [33] were documented. Clinically, high disease activity
(HDA) was deﬁned as DAS28 ≥ 5.1( n = 63) and moderate
disease activity (MDA) as a DAS28 ≥ 3.2–< 5.1( n = 62)
[34]. Erosive disease was deﬁned as the presence of marginal
joint erosions on plain X-rays of the hands and feet. The
study was approved by the Research Ethics Committees of
the Faculties of Health Sciences of the University of Pretoria
and University of the Witwatersrand.
2.2. Laboratory Methods. Venous blood (30mL) was col-
lected in endotoxin-free, silicone-coated vacutainers con-
taining a gel separator. The blood samples were allowed to
stand at room temperature to coagulate (<1 hour) followed
by centrifugation (3000rpm for 10 minutes) after which the
serum was removed, aliquoted, and stored at minus 20◦C
until performance of the various assays described below.
2.2.1. Autoantibodies and Acute Phase Reactants. Rheuma-
toid factor (composite IgM, IgG, IgA), CRP, and SAA were
assayed by nephelometry (Siemens Healthcare Diagnostics,
BN Prospec Nephelometer, Newark, USA). As per supplier
controls, RF, CRP, and SAA results were considered posi-
tive when the concentrations were greater than 11IU/mL,
5μg/mL and 6.8μg/mL, respectively. Anticyclic citrullinated
peptideantibodies(aCCP)weremeasuredbyanimmunoﬂu-
orometric procedure using the Immunocap 250 system and
reagents and controls provided by the manufacturer (Phadia
AB, Uppsala, Sweden), and a concentration >10U/mL
was deemed positive. Antimodiﬁed citrullinated vimentin
antibodies (aMCV) were measured using an ELISA assay
(Orgent ecDiagnostikaGmbH,M ainz,German y),andac on-
centration >20U/mL was deemed positive.
2.2.2. Serum Cytokines, Chemokines, and Growth Factors.
These were measured using the Bio-Plex suspension array
system (Bio-Rad Laboratories Inc, Hercules, CA, USA)
which utilizes Luminex xMAP multiplex technology to
enable simultaneous detection and quantitation of multiple
diﬀerent analytes in a single sample. The system uses an
array of microspheres in liquid suspension, conjugated with
a monoclonal antibody speciﬁc for a target protein. The
beads contain diﬀerent ratios of two spectrally distinct ﬂuo-
rophores, thereby assigning a unique spectral identity. These
antibody-coupled, colour-coded beads were then incubated
with the serum sample (1/4 dilution), washed, followed by
addition of a biotinylated detection antibody, washed again,
and ﬁnally incubated with streptavidin-phycoerythrin. A
wide range of standards (0.38–91756.00pg/mL) was used
to enable quantitation of the individual cytokines using a
Bio-Plex array reader with a dual laser detector and real-
time digital signal processing. The following analytes were
measured simultaneously using a 17-plex test kit: IL-1β,I L -
1Ra, Il-2, IL-4, IL-6, IL-7, IL-8, IL-10, IL-12, IL-17A, IFN-γ,
TNF,G-CSF,GM-CSF,CCL2,CCL4,and VEGF,broadlyrep-
resentative of Th1/Th2/Th17, and macrophage/ﬁbroblasts.
The upper limit of normal for these analytes was calculated
asthemean+1SDfor10healthycontrolsubjects(5female,5
male, averageage 44.4±15.0years, ranging from 26–65years
of age).
2.2.3. Statistical Methods. Statistical Analysis was performed
using STATA statistical software. Correlation coeﬃcients
were derived from correlation matrices using the nonpara-
metric Spearman’s rank correlation test with Holm’s method
P value correction for multiple testing. A P value < .05 was
considered as signiﬁcant.
3.Results
3.1. Demographic, Clinical, and Laboratory (Autoantibodies,
Acute Phase Reactants) Data. These are shown in Tables 1Mediators of Inﬂammation 3
Table 1: Demographic, laboratory, and clinical data for the group of RA patients (n = 140).
Parameters Quintiles
Mean ± SD Q1 (p25) Q2 (Median) Q3 (p75) Range
Age (years) 48 ±12 41 48 56 20–75
Female (%) 115 (82.1)
Ethnic origin: Black (%) 111 (87.0)
DAS28-CRP 5.7 ±1.2 4.8 5.9 6.6 2.3–8.0
HDA (DAS28 ≥ 5.1) (%) 63 (45.0)
LDA (DAS28 ≥ 3.2&<5.1) (%) 62 (44.3)
mHAQ-DI 3.2 ±1.6 2.0 3.5 4.5 0.0–6.0
Disease duration (months) 12 ±7 6 10 18 0–25
SJC 10 ±64 9 1 4 0 – 2 7
X-ray erosions (%) 65/121 (53.7)
RF (IU/mL) 493 ±803 40 171 579 4–5350
aCCP (U/mL) 654 ±621 80 490 1082 2–2431
aMCV (U/mL) 594 ±679 104 326 775 16–3088
CRP (mg/L) 23.0 ±2.5 5.1 13.6 30.6 0.3–164
SAA (μg/mL) 61 ±124 5 16 60 1–882
DAS28: Disease activity score for 28 joints, HDA: High disease activity, LDA: Low disease activity, mHAQ-DI: modiﬁed Health assessment questionnaire-
diseaseIndex, SJC:Swollen JointCount,RF: Rheumatoidfactor,aCCP:anticycliccitrullinatedpeptideantibodies,aMCV: Antimodiﬁedcitrullinatedvimentin
a n t i b o d i e s ,C R P :C - r e a c t i v ep r o t e i n ,S A A :S e r u ma m y l o i dA .
Table 2: Demographic, laboratory, and clinical data for the LDA (n = 62) and HDA (n = 63) groups of RA patients.
Parameters
MDA HDA
Quintiles Quintiles
Mean ± SD Q1 (p25) Q2 (Median) Q3 (p75) Range Mean ± SD Q1 (p25) Q2 (Median) Q3 (p75) Range
Age (years) 46 ± 10 41 45 53 22–68 49 ±12 45 50 57 20–75
Female (%) 47 (75) 50 (80)
Ethnicity: Black (%) 48 (78) 59 (94)
DAS28-CRP 4.5 ± 0.5 4.3 4.7 4.8 3.3–5.0 6.5 ±0.6 6.2 6.6 6.9 5.2–8.7
mHAQ-DI 3.3 ± 1.7 2.0 3.6 4.5 0.0–6.0 1.8 ±0.8 1.3 2.1 2.4 0.0–3.0
Disease duration
(months)
13 ± 8 7 11 20 2–24 11 ±85 9 1 8 2 – 2 4
SJC 5 ± 3 3 5 7 0–15 14 ±6 1 01 31 7 4 – 2 8
X-ray erosions (%) 28/53 (53) 29/57 (51)
RF (IU/mL) 480 ± 681 57 177 559 4–2860 491 ±812 21 178 654 10–5350
aCCP (U/mL) 618 ± 639 51 343 1001 2–2026 734 ±667 89 599 1213 2–2527
aMCV (U/mL) 597 ± 731 90 319 710 20–3028 638 ±727 108 334 868 16–3088
CRP (mg/L) 8 ± 10 2 5 8 1–40 36 ±38 10 27 37 0–198
SAA (μg/mL) 25 ± 48 2 5 24 1–238 91 ±153 8 35 124 1–882
DAS28: Disease activity score for 28 joints, HDA: High disease activity, LDA: Low disease activity, mHAQ-DI: modiﬁed Health assessment questionnaire-
diseaseIndex, SJC:Swollen JointCount,RF: Rheumatoidfactor,aCCP:anticycliccitrullinatedpeptideantibodies,aMCV: Antimodiﬁedcitrullinatedvimentin
a n t i b o d i e s ,C R P :C - r e a c t i v ep r o t e i n ,S A A :S e r u ma m y l o i dA .
and 2forthe totalcohortand the MDAand HDAsubgroups,
respectively. RF, aCCP, and aMCV were positive in 79%,
79%, and 74% of RA patients, respectively, while CRP
and SAA levels were raised in 71% and 68% of patients,
respectively. The mHAQ-DI did not correlate with any of
the laboratory parameters or DAS28, while the DAS28 score
correlated with CRP and SAA (r = 0.52 and r = 0.42,
resp., P<. 0001 for both), in keeping with Emery et al. [35]
Not surprisingly, aCCP and aMCV were strongly correlated
(r = 0.76, P<. 0001) as were CRP and SAA (r = 0.82,
P<. 0001), while only weak correlations were detected be-
tween these autoantibodies and the acute phase reactants.
RF correlated moderately with aCCP and aMCV (r = 0.51,
P = .0002 and r = 0.44, P = .0014, resp.), and weakly with
CRP and SAA (r = 0.2, P<. 02 for both).
3.2. Circulating Cytokines, Chemokines, and Growth Factors
in Healthy Controls and RA Patients. With the exception4 Mediators of Inﬂammation
Table 3: Serum cytokine, chemokine, and growth factor values for the total RA cohort n = 140.
Mean ± SD∗ Q1(p25)∗ Q2 (Median)∗ Q3 (p75)∗ Range∗
IL-1β 24.8 ±48 1.4 5.3 20.0 0–269
IL-Ra 363.5 ±793 25.3 74.8 266.1 0–5012
IL-2 44.7 ±155 0.0 0.0 30.2 0–1320
IL-4 30.5 ±84 0.1 3.6 13.3 0–598
IL-6 64.7 ±130 6.8 18.3 65.5 0–1078
IL-7 221.1 ±741 4.9 22.2 89.5 0–6825
IL-8 295.5 ±3111 5.0 9.3 20.2 0–36699
IL-10 41.6 ±134 3.9 10.7 25.8 0–1172
IL-12 123.9 ±404 2.2 11.0 54.3 1–3105
IL-17A 6.0 ±26 0.0 0.0 0.26 0–229
G-CSF 226.9 ±842 0.0 14.3 57.9 0–8764
GM-CSF 112.8 ±375 0.0 0.0 31.0 0–3726
IFN-γ 580.1 ±1588 0.0 31.3 195.5 0–10922
CCL2 89.0 ±200 0.0 50.7 107.4 0–1771
CCL4 132.6 ±94 70.4 108.2 171.7 27–544
TNF 149.6 ±434 4.3 11.6 61.9 1–2952
VEGF 450.4 ±712 59.4 166.4 518.8 0–4503
∗results in pg/mL.
Table 4: Circulating cytokine data for the MDA (n = 62) and HDA (n = 63) groups of RA patients..
MDA HDA
Cytokines Quintiles Quintiles
Mean±SD Q1 (p25) Q2 (Median) Q3 (p75) Range Mean±SD Q1 (p25) Q2 (Median) Q3 (p75) Range
IL-1β 19 ±29 3 4 26 0–122 30 ±60 1 5 17 0–269
IL-1Ra 291 ±495 28 73 266 0–2994 429 ±973 26 90 252 0–5012
IL-2 33 ±88 0 0 31 0–516 33 ±68 0 0 27 0–297
IL-4 33 ±75 0 5 15 0–361 20 ± 0.46 0 3 11 0–254
IL-6 51 ±79 6 16 60 0–309 73 ± 120 11 27 86 0–792
IL-7 160 ±476 5 21 95 0–3324 282 ±954 7 23 78 0–6852
IL-8 54 ±167 5 9 18 0–997 612 ± 4620 8 11 23 0–36699
IL-10 35 ±82 3 11 22 0–472 51 ± 178 6 10 27 0–1172
IL-12 172 ±401 2 11 48 1–226 117 ±407 3 13 64 1–3105
IL-17A 8 ±37 0 0 0 0–229 3 ±9 0 0 0 0–46
IFN-γ 585 ±1444 3 48 350 0–7541 527 ± 1330 0 27 160 0–6431
G-CSF 181 ±461 1 16 55 0–2285 179 ±423 0 7 64 0–1664
GM-GSF 87 ±211 0 0 24 0–1048 101 ±236 0 0 41 0–978
TNF 161 ±452 5 11 54 1–2952 131 ±392 5 12 69 1–2665
VEGF 475 ±769 54 139 513 0–3582 419 ±502 70 198 534 9–2196
CCL2 69 ±85 0 41 109 0–417 112 ±276 14 55 103 0–1771
CCL4 117 ±64 68 95 163 27–291 159 ±116 89 119 199 32–643
Values in pg/mL.
of TNF, IL-12, G-GSF, and VEGF (mean values of 21 ± 3,
34 ± 37, 34 ± 16, and 176 ± 189pg/mL, resp.), the mean
circulating concentrations of all the other cytokines ranged
from 0–6pg/mL in the group of healthy subjects with no
meaningful diﬀerences between males and females. The
results for the total cohort of RA patients, as well as for
the MDA and HDA subgroups are shown in Tables 3 and
4, respectively. The serum concentrations of the cytokines,
chemokines and growth factors were signiﬁcantly elevated
in the total RA cohort, relative to those of the healthy
control subjects, and those previously reported for healthy
adult humans [36], although the spread of values for each
cytokine was considerable. The only exception was IL17A,
for which only very modest elevations were evident. No
signiﬁcant diﬀerences were observed between the MDA and
HDA groups.Mediators of Inﬂammation 5
Table 5: Correlations between the serum cytokines, chemokines, and growth factor concentrations in the total cohort of RA patients (n =
140).
IL-1β IL-1Ra IL-2 IL-4 IL-6 IL-7 IL-8 IL-10 IL-12 IL-17 G-CSF GM-CSF IFN-γ
TNF 0.85 0.64 0.77 0.86 0.59 0.50 0.23 0.70 0.68 0.52 0.75 0.79 0.81
<.0001 <.0001 <.0001 <.0001 <.0001 <.0001 .0062 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001
IFN-γ 0.86 0.66 0.80 0.95 0.56 0.73 0.31 0.72 0.79 0.50 0.81 0.82
<.0001 <.0001 <.0001 <.0001 <.0001 <.0001 .0002 <.0001 <.0001 <.0001 <.0001 <.0001
GM-CSF 0.86 0.72 0.89 0.87 0.59 0.50 0.26 0.77 0.67 0.48 0.79
<.0001 <.0001 <.0001 <.0001 <.0001 <.0001 .0015 <.0001 <.0001 <.0001 <.0001
G-CSF 0.77 0.62 0.71 0.86 0.47 0.49 0.22 0.63 0.55 0.48
<.0001 <.0001 <.0001 <.0001 <.0001 <.0001 .0083 <.0001 <.0001 <.0001
IL-12 0.84 0.53 0.79 0.82 0.45 0.84 0.35 0.90
<.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001
IL-10 0.80 0.68 0.76 0.73 0.69 0.63 0.23
<.0001 <.0001 <.0001 <.0001 <.0001 <.0001 .0237
IL-7 0.61 0.34 0.61 0.70 0.35
<.0001 <.0001 <.0001 <.0001 <.0001
IL-4 0.88 0.70 0.81
<.0001 <.0001 <.0001
IL-2 0.83 0.77
<.0001 <.0001
IL-1Ra 0.79
<.0001
∗For each pair of values, the correlation coeﬃcient (r) is uppermost with the corresponding P value underneath.
Strong correlations (r ≥ 0.7) are highlighted in bold type, and moderate and weak correlations in plain type.
3.3. Correlations between Cytokines/Chemokines/Growth Fac-
tors. These results are shown in Table 5 with strong cor-
relations highlighted in bold type and moderate and weak
correlations in plain type. Moderate-to-strong correlations
between cytokines of Th1 cell (IL-2, IFN-γ,G M - C S F ) ,
Th2 cell (IL-4, IL-6, IL-10), monocyte/macrophage (IL-
1β, IL-6, IL-12, TNF, G-CSF), and ﬁbroblast (IL-7) origin
were observed in the total cohort of RA patients. Of the
chemokines, only CCL2 was moderately correlated with the
Th1/Th2/macrophage/ﬁbroblast cytokines (r = 0.46–0.66,
P ≤ .0001–.0007). VEGF, perhaps not surprisingly, given
its probable ﬁbroblast and macrophage origins [26, 27],
correlated best with IL-7 (r = 0.55, P<. 0001) and IL-12
(r = 0.45, P = .0009), but only weakly or not at all with
other cytokines.
3.4. Correlations with RF, aCCP, and aMCV. These results
are shown in Table 6 for the total cohort of RA patients.
RF correlated moderately with IL-1β, IL-4, IL-7, IL-12, G-
CSF, GM-CSF, IFN-γ, and TNF and weakly-to-moderately
with IL-Ra, IL-2, IL-6, IL-8, IL-10, IL17A, VEGF, CCL2,
and CCL4. Similar, albeit somewhat weaker, correlations
were observed between these same cytokines and aCCP and
aMCVantibodies.Inthecaseoftheacutephasereactants,IL-
6, not surprisingly, was found to correlate moderately with
CRP and SAA (r = 0.49 and 0.52, resp., P<. 0001 for
both), while weak or no correlations were noted with the
other cytokines (not shown).
Interestingly, VEGF which correlated only weakly with
the Th1/Th2/macrophage/ﬁbroblast cytokines in the total
cohortdemonstrated considerablystrongercorrelationswith
these cytokines in the HDA subgroup. In this subgroup, but
not in the total cohort, strong and signiﬁcant correlations of
VEGF with RF, aCCP, and aMCV were also evident as well
as a weak correlation with X-ray (Larsen) scores as shown in
Table 7.
3.5. Associations of the DAS28 Clinical Scores in the Total
Cohort of Patients and the HDA and MDA Subgroups with
Circulating Biomarkers of Disease Activity. No signiﬁcant
relationships were evidentbetweentheDAS28scores, disease
activity and any of the serum cytokines, chemokines, and
growth factors in the total RA cohort or the MDA subgroup
(data not shown). In the HDA subgroup, however, DAS28
scores, but not disease duration, showed signiﬁcant corre-
lations with serum IFN-γ (r = 0.49, P = .0160), IL-1β
(r = 0.52, P = .0088), IL-1Ra (r = 0.62, P = .0013), TNF
(r = 0.58, P = .0033), and GM-CSF (r = 0.58, P = .0033).
4.Discussion
Multiplex analysis of circulating cytokines in RA has the
potential not only to provide novel insights into the
immunopathogenesis of RA, but also to identify subgroups
of patients at risk for development of severe disease. To
date, however, this important topic has been addressed6 Mediators of Inﬂammation
Table 6: Correlations of RF, aMCV, and aCCP with cytokines, che-
mokines,and growth factors in the total cohort of RA patients (n =
140).
RF aMCV aCCP
IL-1β 0.5199 0.3823 0.3264
0.0001 0.0061 0.0207
IL-1Ra 0.4193 0.4208 ns
0.0024 0.0023
IL-2 0.4737 0.4399 0.3607
0.0005 0.0014 0.0101
IL-4 0.6718 0.5277 0.5096
0.0000 0.0001 0.0002
IL-6 0.3970 0.4693 0.4346
0.0043 0.0006 0.0016
IL-7 0.5021 0.3244 0.3665
0.0002 0.0215 0.0088
IL-8 0.3407 ns ns
0.0155
IL-10 0.4339 0.4540 0.3450
0.0016 0.0009 0.0142
IL-12 0.5732 0.4526 0.4396
0.0000 0.0010 0.0014
IL-17A 0.2910 ns ns
0.0403
G-CSF 0.6254 0.5140 0.4969
0.0000 0.0001 0.0002
GM-CSF 0.6150 0.5639 0.4552
0.0000 0.0000 0.0009
IFN-γ 0.6561 0.5562 0.5473
0.0000 0.0000 0.0000
TNF 0.5667 0.4920 0.4120
0.0000 0.0003 0.0029
VEGF 0.4405 ns ns
0.0014
CCL2 0.3624 ns ns
0.0097
CCL4 0.3597 0.4444 0.3790
0.0103 0.0012 0.0066
RF: Rheumatoid factor, aCCP: anticyclic citrullinated peptide antibodies,
aMCV: Antimutatedcitrullinated vimentin antibodies.
ns: not signiﬁcant.
in a limited number of studies [16, 19, 20, 22–25, 37].
These have shown promise, particularly two recent studies
which have described generalised elevations in circulating
cytokines, especially Th1/Th2/macrophage cytokines, which
precede the onset of clinical disease and are also markers
of disease severity [20, 37, 38]. However, there is clearly a
need for corroboration and extension in larger groups of
patients. In the current study, we have investigated circulat-
ing cytokine proﬁles, representative of Th1, Th2, and Th17
cells, monocytes/macrophages, and ﬁbroblasts, in a large
group of DMARD-na¨ ıve RA patients of disease duration
<2 years. Notwithstanding characterization of circulating
Table 7: Correlations of VEGF with autoantibodies, circulating
cytokines, and X-ray scores in the total cohort (n = 140) and HDA
group (n = 63).
Total HDA
r(p) r(p)
RF 0.44 (0.0014) 0.60 (0.0023)
SAA ns ns
CRP ns ns
aMCV ns 0.59 (0.0023)
aCCP ns 0.67 (0.0003)
IL-1β 0.29 (0.0433) 0.48 (0.0190)
IL-1Ra ns 0.41 (0.0474)
IL-2 0.40 (0.0038) 0.61 (0.0014)
IL-4 0.36 (0.0098) 0.65 (0.0006)
IL-7 0.55 (<0.0000) 0.65 (0.0006)
IL-8 ns 0.41 (0.0448)
IL-10 0.38 (0.0072) 0.46 (0.0246)
IL-12 0.46 (0.0009) 0.60 (0.0021)
G-CSF 0.31 (0.0306) 0.55 (0.0052)
GM-CSF 0.37 (0.0086) 0.69 (0.0002)
IFN-γ 0.37 (0.0082) 0.66 (0.0004)
TNF ns 0.53 (0.0078)
CCL2 0.40 (0.0044) ns
CCL4 ns 0.56 (0.0044)
Larsen ns 0.42 (0.0409)
RF: Rheumatoid factor, SAA: Serum amyloid A, CRP: C-reactive protein,
aCCP: anticyclic citrullinated peptide antibodies, aMCV: Antimodiﬁed
citrullinated vimentin antibodies.
ns: not signiﬁcant.
cytokine proﬁles, the major objectives of the current study
were to identify inter-relationships between cytokines, as
well as correlations with RA-associated autoantibodies, acute
phase reactants, and clinical disease activity. These were
analysed in the totalcohort ofpatients, as well as in theMDA
and HDA subgroups.
In the case of the total cohort, and in keeping with
previous studies [16, 19, 20, 22–25, 37], we observed a
general increase in the circulating levels of all of the anti-
inﬂammatory/proinﬂammatory cytokines, growth factors
and chemokines. IL17A was the exception, being barely
detectable and only modestly intercorrelated with the other
cytokines. In contrast, cytokines primarily of Th1 and
Th2 lymphocyte origin, as well as those derived mainly
from monocytes/macrophages and ﬁbroblasts, were not only
elevated, but also highly intercorrelated in the total cohort,
and strongest in the HDA subgroup. The strong correlations
of the Th2 cytokines, IL-4, and IL-10 [39], with those of
the proinﬂammatory cytokines, IL-1β,I L - 2 ,I L - 6 ,I L - 7 ,I L -
12, G-CSF, GM-CSF, IFN-γ, and TNF, probably reﬂect the
eﬀorts of these cells to suppress the reactivity of their Th1
counterparts, and to redirect the phenotype and functions
of classically IFN-γ-activated M1 macrophages [40, 41]. It
is, however, noteworthy that IL-10 also originates from cell
types other than Th2 cells, and M2-derived IL-10 is also
likely to fulﬁll an anti-inﬂammatory function underscoringMediators of Inﬂammation 7
the plasticity of transitions between various cell phenotypes
according to the cytokine environment. Notwithstanding its
anti-inﬂammatory activity, IL-4 may also play a proinﬂam-
matory role in RA by driving the activity of autoreactive
B cells, possibly underscored by the associations of IL-
4 with aCCP and aMCV. In addition to eﬀects on Th1
cells and M1 macrophages, the Th2 cytokines IL-4 and
IL-10 also suppress the proliferation and proinﬂammatory
activities of ﬁbroblasts [42–45]. Importantly, the consistency
and magnitude of the correlations between the cytokines
suggest that these are unlikely to be spurious, and also attest
to the robustness of the multiplex cytokine assay system.
Althoughourgroup ofhealthy control subjectswas relatively
small (n = 10), their low levels of circulating cytokines are
comparable with those reported from a much larger series of
healthy subjects [36].
In keepingwith the increasing recognition ofthe involve-
ment of IL-7 in orchestrating chronic inﬂammation in the
rheumatoid joint [46–50], this cytokine was found to be
highly correlated with IL-12 in particular, as well as with
IFN-γ. Synovial ﬁbroblasts, activated by IL-1β and TNF, as
well as macrophages, are likely to be the major source of
IL-7. Interestingly, the predominant lymphocyte subset in
the rheumatoid joint has been reported to be of the Th1
eﬀector-memory phenotype, expressing functional IL-12R,
IL-18 Rα, and CCR5 [11]. These cells are directly activated
to secrete IFN-γ by cytokines such as IL-2, IL-7, and IL-
15, but not IL-4, which signal via the IL-2R common γ-
chainincombinationwithIL-12andIL-18,independentlyof
TCR ligation [11]. Although of considerable interest, further
studies are necessary to conﬁrm the role of this autoantigen-
independent mechanism of perpetuation of inﬂammation in
RA.
Circulating IFN-γ was strongly correlated with the
predominantly macrophage-derived cytokines IL-1β, IL-12,
TNF, and G-CSF. This is in keeping with the classically,
IFN-γ-activated macrophage of the M1 phenotype being a
major source of proinﬂammatory cytokines in the inﬂamed
RA joint [51]. Of the 3 chemokines measured, IL-8, CCL2,
and CCL4, only CCL2 showed moderate correlations with
the various Th1/Th2, macrophage and ﬁbroblast cytokines,
in the total cohort, possibly reﬂecting the predominantly
macrophage/ﬁbroblast origins of this monocyte-targeted
chemokine.
Circulating VEGF, which has been reported to predict
disease severity and progression in RA [28, 29, 52], corre-
lated poorly with the other cytokines with the exceptions
of IL-7 in particular, and IL-12, possibly reﬂecting the
ﬁbroblast and macrophage origins, respectively, of VEGF
[26, 27]. However, when the total cohort of RA patients
was subdivided into those with MDA and HDA, signif-
icant correlations were observed between VEGF and the
Th1/Th2/macrophage/ﬁbroblast cytokines, as well as with
RF, aCCP, and aMCV in the HDA group, substantiating the
role of VEGF as a predictor of severity of disease in our
cohort.
With respect to correlations of the Th1, Th2, Th17,
monocyte/macrophage, and ﬁbroblast cytokines, with tra-
ditional biomarkers of disease activity in the total cohort,
RF correlated moderately with IL-1β, IL-4, IL-7, IL-12, G-
CSF, GM-CSF, IFN-γ, and TNF, with weaker, but nonethe-
less signiﬁcant correlations detected between these same
cytokines, and aCCP and aMCV. Not surprisingly, the acute
phase reactants, CRP and SAA, correlated best with IL-6,
while weak correlations were evident with most of the other
cytokines. Given the strong association of RF, aCCP, and
aMCV with disease severity and poor prognosis in RA
[53–56], these ﬁndings are compatible with the involvement
of the Th1 lymphocyte/macrophage/ﬁbroblast axis in the
immunopathogenesis of RA [5, 57]. This contention is
underscored by thesigniﬁcant cor-relationsofIL-1β,I L - 1 R a ,
TNF, IFN-γ, and GM-CSF with the DAS28 score observed
in the HDA subgroup. Although a role for Th2 cells in
disease pathogenesis cannot be excluded, the association
of the Th2 cytokines, IL-4, and IL-10, with RF, aCCP,
and aMCV most likely reﬂects their anti-inﬂammatory
activities. A dynamic interaction between the production
of Th1 and Th2 cytokines with opposing pro- and anti-
inﬂammatory activities may regulate the rate and severity
of damage to cartilage and bone in established RA. This
in turn may explain the relatively weak correlations of
acute phase reactants with cytokines and autoantibod-
ies.
Transiently elevated concentrations of cytokine in syn-
ovialﬂuidhavebeenreportedwithcertaincytokinesofTcell,
macrophage, and stromal cell origin being elevated in early
disease, but apparently undetectable in established disease
[58]. The inﬂamed synovium is inﬁltrated by pathogenic
eﬀectorTcellsand autoreactiveBcellsactivated byunknown
triggers where they orchestrate local joint inﬂammation. It
has been clearly demonstrated that the elevated synovial, as
well as circulating cytokines, are a common manifestation
of the persistent state of inﬂammation and are predictive of
disease severity [1, 16, 20, 24, 38, 58–62].
The limitations of the current study include our focus on
circulating, as opposed to synovial cytokines [63], as well as
the recruitment of patients with established, rather than very
early disease. In defence of these strategies, measurement
of synovial cytokines presents logistical and ethical issues
and is relatively impractical from a laboratory diagnostic
perspective, while identiﬁcation of patients with very early
disease is particularly diﬃcult in the health care setting of
a developing country. The strengths of the study, on the
other hand, include the relatively large number of patients
recruited to the study, all of whom were DMARD-na¨ ıve, as
well as the range of circulating markers of disease activity
which were evaluated.
In conclusion, the current study has demonstrated a
circulating cytokine proﬁle in patients with established
RA which appears compatible with Th1 cell/macrophage/
ﬁbroblast activation and a possible counter-regulatory role
of Th2 cells. This is underscored by relatively strong
correlations between cytokines and established biomarkers,
especially RF, as well as aCCP and aMCV antibodies. IL-1β,
IL-1Ra, TNF, IFN-γ, GM-CSF, and VEGF in particular
were signiﬁcantly associated with HDA and show prom-
ise as adjunctive diagnostic/prognostic biomarkers, either
individually or in combination. The clinical utility of this8 Mediators of Inﬂammation
strategy will, however, depend on the outcome of large,
multicentre follow-up studies.
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